Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, before the U.S. market open. A live webcast with management will follow at 8:00 a.m. Eastern Time and will be posted on the company’s Investor Relations website approximately two hours later. Participants are advised to register at least 15 minutes before the webcast for a timely connection.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
MDGL was down 1.09% while close peers showed mixed, mostly modest moves (e.g., VRNA slightly positive, ROIV and MRNA negative). No peers appeared in the momentum scanner, indicating this earnings-date news is stock-specific rather than part of a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 22 | Inducement equity grants | Neutral | +0.2% | Grants of options and RSUs to 40 new non-executive employees. |
| Jan 21 | Executive inducement award | Neutral | +0.2% | Inducement RSUs and options granted to new Chief Accounting Officer. |
| Jan 09 | Pipeline license deal | Positive | -7.6% | Exclusive global license from Pfizer for Phase 2 DGAT-2 inhibitor ervogastat. |
| Dec 18 | Employee RSU grants | Neutral | -0.3% | Inducement RSUs to four new non-executive employees under 2025 plan. |
| Dec 15 | Conference presentation | Neutral | -1.1% | Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
Recent MDGL news has been operational and corporate (inducement grants, conferences, pipeline expansion). Price reactions were generally modest, with small gains on inducement awards and mild declines on pipeline and conference updates, suggesting the stock has not strongly overreacted to routine corporate disclosures in the past few months.
Over the last six weeks, Madrigal’s news flow featured inducement equity awards to new hires and employees, an expanded MASH pipeline via a licensed Phase 2 DGAT-2 inhibitor, and a major healthcare conference appearance. The pipeline license on Jan 9, 2026 saw the sharpest reaction at -7.58%, while multiple inducement announcements on Dec 18, 2025 and Jan 21–22, 2026 produced minimal moves near flat. Against this backdrop, today’s scheduling of the Q4 and full-year 2025 results sets timing for a potentially more material update than recent routine disclosures.
Market Pulse Summary
This announcement sets the date and webcast details for Madrigal’s Q4 and full-year 2025 financial results on February 19, 2026. It provides a clear timing marker for when more fundamental information will arrive, but contains no financial metrics or guidance changes. In the context of recent routine corporate updates and regulatory filings, the key focus shifts to the upcoming earnings release, where revenue trends, cash position, and any updated outlook will be critical to monitor.
AI-generated analysis. Not financial advice.
CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com
FAQ
When will Madrigal Pharmaceuticals (MDGL) release Q4 and FY2025 results?
What time is the Madrigal (MDGL) earnings webcast on Feb. 19, 2026?
Where can investors access Madrigal Pharmaceuticals (MDGL) Feb. 19, 2026 webcast?
Will Madrigal (MDGL) provide a replay of the Feb. 19, 2026 webcast?
Do investors need to register for Madrigal Pharmaceuticals (MDGL) Feb. 19 webcast?
